

## **Amendments**

### **Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

#### **Listing of Claims:**

Claim 1 (original) A salt of nateglinide having a melting point in the range of 50 to 300 °C.

Claim 2 (original) A salt of nateglinide according to claim 1 having a melting point in the range of 50 to 125 °C.

Claim 3 (original) A salt of nateglinide according to claim 1 having a melting point in the range of 150 to 300 °C.

Claim 4 (original) A salt of nateglinide having a solubility in water of at least 0.18 mg/ml.

Claim 5 (original) A salt of nateglinide according to claim 4 having a solubility in water of at least 0.4 mg/ml.

Claim 6 (original) A salt of nateglinide according to claim 5 having a solubility in water of at least 40 mg/ml.

Claim 7 (currently amended) A salt of nateglinide according to claim 1 having an X-ray powder diffraction (XRPD) pattern that comprises a combination of reflection maxima of any of Compounds 1-19 as set forth in Table IV.

Claim 8 (original) A salt of nateglinide according to claim 7, which is present in an amorphous form.

Claim 9 (original) A salt of nateglinide according to claim 7, which is present in a crystalline form.

Claim 10 (original) A salt of nateglinide according to claim 7, which is present as a mixture of an amorphous form and a crystalline form.

Claim 11 (previously amended) A salt of nateglinide according to claim 1, in which the cation is selected from the group consisting of Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>2+</sup>, Mg<sup>2+</sup>, the protonated form of

Tris(hydroxymethyl)-aminomethane, the protonated form of N-methyl-D-glucamine and a protonated form of Lysine.

Claim 12 (original) A salt of nateglinide according to claim 11, in which the ratio of the nateglinide anion to the cation is 1:1.

Claim 13 (original) A salt of nateglinide according to claim 11, in which the ratio of the nateglinide anion to the cation is 2:1.

Claim 14 (previously amended) A salt of nateglinide according to claim 1 that loses between 0.1 and 14 % of its mass on heating.

Claim 15 (original) A salt of nateglinide according to claim 14 that loses between 0.1 and 9 % of its mass on heating.

Claim 16 (previously amended) A salt of nateglinide according to claim 1 having a bulk density between 0.1 and 0.6 g/cm<sup>3</sup>.

Claim 17 (previously amended) A composition comprising a salt of nateglinide according to claim 1.

Claim 18 (original) A composition according to claim 17 comprising one or more additional ingredients selected from the group consisting of vitamins, nutrition supplements and pharmaceutically active substances.

Claim 19 (original) A composition according to claim 18 comprising nateglinide or repaglinide as additional ingredient.

Claim 20 (original) A composition according to claim 18 wherein the pharmaceutically active substance is selected from the group consisting of insulin sensitizers, insulin secretion enhancers, Dipeptidyl peptidase IV inhibitors, ACE inhibitors and angiotensin II inhibitors.

Claim 21 (original) A composition according to claim 18, which is a combined preparation or pharmaceutical composition.

Claim 22 (original) A pharmaceutical composition according to claim 21 for the treatment of diabetes, cardiovascular diseases, or conditions associated therewith.

Claim 23 (currently amended) A method of treatment of diabetes, ~~cardiovascular diseases, or conditions associated therewith~~ comprising the administration, to a mammal in need of such treatment, of an effective amount a salt of nateglinide according to claim 1.

Claim 24 (cancelled)